 Leukemia, Myeloid, Acute
"Leukemia, Myeloid, Acute" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
| Descriptor ID |
D015470
|
| MeSH Number(s) |
C04.557.337.539.550
|
| Concept/Terms |
Leukemia, Myeloid, Acute- Leukemia, Myeloid, Acute
- ANLL
- Leukemia, Myeloblastic, Acute
- Leukemia, Myelocytic, Acute
- Leukemia, Myelogenous, Acute
- Nonlymphocytic Leukemia, Acute
- Acute Nonlymphocytic Leukemia
- Acute Nonlymphocytic Leukemias
- Leukemia, Acute Nonlymphocytic
- Leukemias, Acute Nonlymphocytic
- Nonlymphocytic Leukemias, Acute
- Leukemia, Nonlymphocytic, Acute
- Myeloblastic Leukemia, Acute
- Acute Myeloblastic Leukemia
- Acute Myeloblastic Leukemias
- Leukemia, Acute Myeloblastic
- Leukemias, Acute Myeloblastic
- Myeloblastic Leukemias, Acute
- Myelocytic Leukemia, Acute
- Acute Myelocytic Leukemia
- Acute Myelocytic Leukemias
- Leukemia, Acute Myelocytic
- Leukemias, Acute Myelocytic
- Myelocytic Leukemias, Acute
- Myelogenous Leukemia, Acute
- Acute Myelogenous Leukemia
- Acute Myelogenous Leukemias
- Leukemia, Acute Myelogenous
- Leukemias, Acute Myelogenous
- Myelogenous Leukemias, Acute
- Myeloid Leukemia, Acute
- Nonlymphoblastic Leukemia, Acute
- Acute Nonlymphoblastic Leukemia
- Acute Nonlymphoblastic Leukemias
- Leukemia, Acute Nonlymphoblastic
- Leukemias, Acute Nonlymphoblastic
- Nonlymphoblastic Leukemias, Acute
- Acute Myeloid Leukemia
- Acute Myeloid Leukemias
- Leukemia, Acute Myeloid
- Leukemias, Acute Myeloid
- Myeloid Leukemias, Acute
- Leukemia, Nonlymphoblastic, Acute
|
Below are MeSH descriptors whose meaning is more general than "Leukemia, Myeloid, Acute".
Below are MeSH descriptors whose meaning is more specific than "Leukemia, Myeloid, Acute".
- Leukemia, Myeloid, Acute
- Leukemia, Basophilic, Acute
- Leukemia, Eosinophilic, Acute
- Leukemia, Erythroblastic, Acute
- Leukemia, Mast-Cell
- Leukemia, Megakaryoblastic, Acute
- Leukemia, Monocytic, Acute
- Leukemia, Promyelocytic, Acute
This graph shows the total number of publications written about "Leukemia, Myeloid, Acute" by people in this website by year, and whether "Leukemia, Myeloid, Acute" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1980 | 3 | 1 | 4 | | 1981 | 1 | 3 | 4 | | 1982 | 0 | 2 | 2 | | 1983 | 2 | 0 | 2 | | 1984 | 2 | 0 | 2 | | 1986 | 2 | 0 | 2 | | 1987 | 1 | 0 | 1 | | 1988 | 4 | 0 | 4 | | 1989 | 6 | 0 | 6 | | 1990 | 2 | 0 | 2 | | 1991 | 4 | 1 | 5 | | 1992 | 4 | 0 | 4 | | 1993 | 9 | 1 | 10 | | 1994 | 4 | 1 | 5 | | 1995 | 3 | 1 | 4 | | 1996 | 2 | 2 | 4 | | 1997 | 2 | 2 | 4 | | 1998 | 3 | 1 | 4 | | 1999 | 2 | 1 | 3 | | 2000 | 6 | 1 | 7 | | 2001 | 4 | 0 | 4 | | 2002 | 7 | 2 | 9 | | 2003 | 7 | 0 | 7 | | 2004 | 4 | 1 | 5 | | 2005 | 5 | 0 | 5 | | 2006 | 7 | 1 | 8 | | 2007 | 8 | 1 | 9 | | 2008 | 16 | 0 | 16 | | 2009 | 17 | 0 | 17 | | 2010 | 16 | 1 | 17 | | 2011 | 15 | 2 | 17 | | 2012 | 23 | 1 | 24 | | 2013 | 25 | 1 | 26 | | 2014 | 23 | 0 | 23 | | 2015 | 28 | 0 | 28 | | 2016 | 20 | 3 | 23 | | 2017 | 15 | 5 | 20 | | 2018 | 20 | 2 | 22 | | 2019 | 20 | 1 | 21 | | 2020 | 21 | 2 | 23 | | 2021 | 24 | 0 | 24 | | 2022 | 16 | 0 | 16 | | 2023 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Leukemia, Myeloid, Acute" by people in Profiles.
-
de Botton S, Montesinos P, Schuh AC, Papayannidis C, Vyas P, Wei AH, Ommen H, Semochkin S, Kim HJ, Larson RA, Koprivnikar J, Frankfurt O, Thol F, Chromik J, Byrne J, Pigneux A, Thomas X, Salamero O, Vidriales MB, Doronin V, Döhner H, Fathi AT, Laille E, Yu X, Hasan M, Martin-Regueira P, DiNardo CD. Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial. Blood. 2023 Jan 12; 141(2):156-167.
-
Larkin KT, Nicolet D, Kelly BJ, Mrózek K, LaHaye S, Miller KE, Wijeratne S, Wheeler G, Kohlschmidt J, Blachly JS, Mims AS, Walker CJ, Oakes CC, Orwick S, Boateng I, Buss J, Heyrosa A, Desai H, Carroll AJ, Blum W, Powell BL, Kolitz JE, Moore JO, Mayer RJ, Larson RA, Stone RM, Paskett ED, Byrd JC, Mardis ER, Eisfeld AK. High early death rates, treatment resistance, and short survival of Black adolescents and young adults with AML. Blood Adv. 2022 10 11; 6(19):5570-5581.
-
Döhner H, Weber D, Krzykalla J, Fiedler W, Wulf G, Salih H, Lübbert M, Kühn MWM, Schroeder T, Salwender H, Götze K, Westermann J, Fransecky L, Mayer K, Hertenstein B, Ringhoffer M, Tischler HJ, Machherndl-Spandl S, Schrade A, Paschka P, Gaidzik VI, Theis F, Thol F, Heuser M, Schlenk RF, Bullinger L, Saadati M, Benner A, Larson R, Stone R, Döhner K, Ganser A. Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications. Blood Adv. 2022 09 27; 6(18):5345-5355.
-
Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA, Levine RL, Miyazaki Y, Niederwieser D, Ossenkoppele G, Röllig C, Sierra J, Stein EM, Tallman MS, Tien HF, Wang J, Wierzbowska A, Löwenberg B. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022 09 22; 140(12):1345-1377.
-
Aivalioti MM, Bartholdy BA, Pradhan K, Bhagat TD, Zintiridou A, Jeong JJ, Thiruthuvanathan VJ, Pujato M, Paranjpe A, Zhang C, Levine RL, Viny AD, Wickrema A, Verma A, Will B. PU.1-Dependent Enhancer Inhibition Separates Tet2-Deficient Hematopoiesis from Malignant Transformation. Blood Cancer Discov. 2022 09 06; 3(5):444-467.
-
Konopleva M, Thirman MJ, Pratz KW, Garcia JS, Recher C, Pullarkat V, Kantarjian HM, DiNardo CD, Dail M, Duan Y, Chyla B, Potluri J, Miller CL, Wei AH. Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia. Clin Cancer Res. 2022 07 01; 28(13):2744-2752.
-
Albert DH, Goodwin NC, Davies AM, Rowe J, Feuer G, Boyiadzis M, Dorritie KA, Mancini M, Gandour-Edwards R, Jonas BA, Borthakur G, Aldoss I, Rizzieri DA, Odenike O, Prebet T, Singh S, Popovic R, Shen YU, McDaniel KF, Kati WM, Modi DA, Motwani M, Wolff JE, Frost DJ. Co-clinical Modeling of the Activity of the BET Inhibitor Mivebresib (ABBV-075) in AML. In Vivo. 2022 Jul-Aug; 36(4):1615-1627.
-
Weinberg OK, Arber DA. How I Diagnose Acute Leukemia of Ambiguous Lineage. Am J Clin Pathol. 2022 07 01; 158(1):27-34.
-
Ritchie EK, Klepin HD, Storrick E, Major B, Le-Rademacher J, Wadleigh M, Walker A, Larson RA, Roboz GJ. Geriatric assessment for older adults receiving less-intensive therapy for acute myeloid leukemia: report of CALGB 361101. Blood Adv. 2022 06 28; 6(12):3812-3820.
-
Perl AE, Larson RA, Podoltsev NA, Strickland S, Wang ES, Atallah E, Schiller GJ, Martinelli G, Neubauer A, Sierra J, Montesinos P, Récher C, Yoon SS, Hosono N, Onozawa M, Chiba S, Kim HJ, Hasabou N, Lu Q, Tiu R, Levis MJ. Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. Blood. 2022 06 09; 139(23):3366-3375.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|